TRAF6 and hepatocellular carcinoma: Additionally, Research in HCC models (e.g., Hep3B and Huh7 cells) has reported that AT-II can increase the proportion of CD8+ T cells and IFN-γ levels while decreasing IL-10 levels and PD-L1 expression, suggesting a role in modulating immune evasion through the TRAF6/NF-κB pathway [63].